GTBP GT Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GTBP

Price (delayed)

$3.3

Market cap

$4.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.64

Enterprise value

$3.54M

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform ...

Highlights
GTBP's EPS has soared by 71% year-on-year and by 36% since the previous quarter
The debt has shrunk by 67% YoY and by 37% QoQ
GT Biopharma's quick ratio has decreased by 37% YoY and by 33% QoQ
GT Biopharma's equity has decreased by 36% YoY and by 25% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.gtbiopharma.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of GTBP
Market
Shares outstanding
1.38M
Market cap
$4.56M
Enterprise value
$3.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$7.38M
EBITDA
-$7.38M
Free cash flow
-$8.85M
Per share
EPS
-$5.64
Free cash flow per share
-$6.57
Book value per share
$5.41
Revenue per share
$0
TBVPS
$10.47
Balance sheet
Total assets
$14.11M
Total liabilities
$6.63M
Debt
$58,000
Equity
$7.48M
Working capital
$7.42M
Liquidity
Debt to equity
0.01
Current ratio
2.12
Quick ratio
2.11
Net debt/EBITDA
0.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-44.4%
Return on equity
-71.8%
Return on invested capital
-74.4%
Return on capital employed
-98.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GTBP stock price

How has the GT Biopharma stock price performed over time
Intraday
4.43%
1 week
1.54%
1 month
-28.88%
1 year
-63.09%
YTD
-56.86%
QTD
-25.84%

Financial performance

How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.58M
Net income
-$7.6M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 64% YoY and by 26% QoQ
GTBP's operating income is up by 36% year-on-year and by 16% since the previous quarter

Growth

What is GT Biopharma's growth rate over time

Valuation

What is GT Biopharma stock price valuation
P/E
N/A
P/B
0.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS has soared by 71% year-on-year and by 36% since the previous quarter
The price to book (P/B) is 49% lower than the last 4 quarters average of 1.2
GT Biopharma's equity has decreased by 36% YoY and by 25% QoQ

Efficiency

How efficient is GT Biopharma business performance
The ROIC has soared by 63% YoY and by 26% from the previous quarter
The company's return on assets has surged by 52% YoY and by 23% QoQ
GTBP's ROE is up by 48% year-on-year and by 18% since the previous quarter

Dividends

What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GTBP.

Financial health

How did GT Biopharma financials performed over time
GT Biopharma's total assets is 113% more than its total liabilities
GT Biopharma's current ratio has decreased by 37% YoY and by 33% QoQ
GT Biopharma's quick ratio has decreased by 37% YoY and by 33% QoQ
The debt is 99% lower than the equity
The debt has shrunk by 67% YoY and by 37% QoQ
GT Biopharma's equity has decreased by 36% YoY and by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.